Clinical Trials · NCT03466216

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

TerminatedPhase 1Octreotide (Prohibited)
Phase
Phase 1
Recruitment status
Terminated
Sponsor
Orano Med LLC
Enrollment
33
Start date
Feb 2018
Locations
1 site, United States
Primary endpoint
To determine dose-limiting toxicity (DLT)
View Octreotide compound reference